Skip to main content
. 2017 Mar 15;8(2):141–146. doi: 10.1007/s12687-017-0295-7

Fig. 1.

Fig. 1

a Unadjusted proportion of women who received BRCA1/2 testing for the management of breast cancer risk, by year. b BRCA1/2 test mean costs by patients and payers, by year. Comparison of mean insurance reimbursement and patient out-of-pocket spending was estimated using a generalized estimating equation with log link and normal distribution for before and after Jolie’s announcement in 05/2013